Hemosol (NASDAQ:HMSL)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Hemosol Charts. Click Here for more Hemosol Charts.](/p.php?pid=staticchart&s=N%5EHMSL&p=8&t=15)
Hemosol to Host Annual and Special Meeting of Shareholders June
7, 2005
TORONTO, May 31 /PRNewswire-FirstCall/ -- Hemosol Inc. (NASDAQ:HMSLNASDAQ:TSX:
HML) today announced that the Company will hold its Annual and Special Meeting
of Shareholders at the TSX Broadcast Centre, Gallery Room, 130 King Street
West, Toronto, Ontario, beginning at 10:00 am (EST) on June 7th, 2005.
An information circular was mailed to shareholders on May 17, 2005 describing
the formal business to be dealt with at the meeting. Subsequent to that
mailing, Hemosol's Board has approved the addition of Dr. Paul Walker to the
slate of nominees to stand for election as Directors of the corporation.
Dr. Walker is the President & CEO, as well as a Director of Spectral
Diagnostics Inc. Prior to accepting this corporate position, he was Chief
Operating Officer of the Toronto General Hospital. His medical career included
being Surgeon-in-Chief of the University Hospital Network and Professor of
Medicine and Laboratory Medicine at the University of Toronto. He received his
M.D. from the University of Western Ontario, his PhD from the Salgrenska
University of Goteborg Sweden, and is the author of more than 100 scientific
publications. Dr. Walker is a also a graduate of the Advanced Management
Program from Harvard School of Business.
Following the conclusion of the formal business portion of the meeting, Lee
Hartwell, Hemosol's President & CEO, along with other members of the senior
management team, will provide a presentation covering the Company's
accomplishments in 2004 and goals and objectives for 2005.
An audio version of the meeting will be available on the Internet. To access
the live webcast please visit http://www.hemosol.com/. The broadcast will be
archived for up to 12 months. To listen to the presentation you will need a
standard web browser equipped with Windows media player.
About Hemosol
Hemosol is a biopharmaceutical company focused on the development and
manufacturing of biologics, particularly blood-related proteins. Hemosol has a
broad range of novel therapeutic products in development, including oxygen
therapeutics and protein-based therapeutics to treat certain infectious
diseases, cancers and anemia.
For more information visit Hemosol's website at http://www.hemosol.com/.
The Common Shares are listed on the NASDAQ Stock Market under the trading
symbol "HMSL" and on the TSX under the trading symbol "HML".
Certain statements concerning Hemosol's future prospects are "forward- looking
statements" within the meaning of the United States Private Securities
Litigation Reform Act of 1995 and other applicable securities legislation.
There can be no assurances that future results will be achieved, and actual
results could differ materially from forecasts and estimates. Important factors
that could cause actual results to differ materially from forecasts and
estimates include, but are not limited to: Hemosol's ability to successfully
implement the Cascade technology and commercialize products derived there from;
Hemosol's ability to obtain additional financing which is critical to the
implementation of the Cascade technology and to Hemosol's continued viability
as a going concern; Hemosol's ability to obtain regulatory approvals for its
products; Hemosol's ability to successfully complete clinical trials for its
products; Hemosol's ability to enter into satisfactory arrangements for the
supply of materials used in its manufacturing operations and the sale of
resulting products to customers; technical, manufacturing or distribution
issues; the competitive environment for Hemosol's products and services; the
degree of market penetration of Hemosol's products; Hemosol's ability to
attract and retain clients for its bio-manufacturing services; the risk that
Hemosol may not become profitable; and other factors set forth in filings with
Canadian securities regulatory authorities and the U.S. Securities and Exchange
Commission. These risks and uncertainties, as well as others, are discussed in
greater detail in the filings of Hemosol with Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission. Hemosol makes no
commitment to revise or update any forward-looking statements in order to
reflect events or circumstances after the date any such statement is made.
DATASOURCE: Hemosol Corp.
CONTACT: Jason Hogan, Investor & Media Relations, (416) 361-1331,
(800) 789-3419, (416) 815-0080 fax, , http://www.hemosol.com/;
Archived images on this organization are searchable through CNW Photo Archive
website at http://photos.newswire.ca/. Images are free to accredited members of
the media. To request a free copy of this organization's annual report, please
go to http://www.newswire.ca/ and click on reports@cnw.